Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 36.

Mangani, D; Weller, M; Seyed Sadr, E; Willscher, E; Seystahl, K; Reifenberger, G; Tabatabai, G; Binder, H; Schneider, H (2016). Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models. Neuro-Oncology, 18(12):1610-1621.

Niessner, H; Schmitz, J; Tabatabai, G; et al; Dummer, Reinhard (2016). PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo. Clinical Cancer Research, 22(23):5818-5828.

Suchorska, B; Weller, M; Tabatabai, G; Senft, C; Hau, P; Sabel, M C; Herrlinger, U; Ketter, R; Schlegel, U; Marosi, C; Reifenberger, G; Wick, W; Tonn, J C; Wirsching, H G (2016). Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology, 18(4):549-556.

Krishnan, S; Szabo, E; Burghardt, I; Frei, K; Tabatabai, G; Weller, M (2015). Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. OncoTarget, 6(26):22480-22495.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Seystahl, K; Tritschler, I; Szabo, E; Tabatabai, G; Weller, M (2015). Differential regulation of TGF-β-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. Neuro-Oncology, 17(2):254-265.

Eisele, G; Wick, A; Eisele, A C; Clément, P M; Tonn, J; Tabatabai, G; Ochsenbein, A; Schlegel, U; Neyns, B; Krex, D; Simon, M; Nikkhah, G; Picard, M; Stupp, R; Wick, W; Weller, M (2014). Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of Neuro-Oncology, 117(1):141-145.

Gulbins, E; Palmada, M; Reichel, M; Lüth, A; Böhmer, C; Amato, D; Müller, C P; Tischbirek, C H; Groemer, T W; Tabatabai, G; Becker, K A; Tripal, P; Staedtler, S; Ackermann, T F; van Brederode, J; Alzheimer, C; Weller, M; Lang, U E; Kleuser, B; Grassme, H; Kornhuber, J (2013). Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nature Medicine, 19(7):934-938.

Spescha, R D; Shi, Y; Wegener, S; Keller, S; Weber, B; Wyss, M M; Lauinger, N; Tabatabai, G; Paneni, F; Cosentino, F; Hock, C; Weller, M; Nitsch, R M; Lüscher, T F; Camici, G G (2013). Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. European Heart Journal, 34(2):96-103.

Gramatzki, D; Herrmann, C; Happold, C; Becker, K A; Gulbins, E; Weller, M; Tabatabai, G (2013). Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. PLoS ONE, 8(5):e63527.

Roth, P; Silginer, M; Goodman, S L; Hasenbach, K; Thies, S; Maurer, G; Schraml, P; Tabatabai, G; Moch, H; Tritschler, I; Weller, M (2013). Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain, 136(2):564-576.

Wick, W; Meisner, C; Hentschel, B; Platten, M; Schilling, A; Wiestler, B; Sabel, M C; Koeppen, S; Ketter, R; Weiler, M; Tabatabai, G; von Deimling, A; Gramatzki, D; Westphal, M; Schackert, G; Loeffler, M; Simon, M; Reifenberger, G; Weller, M (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81(17):1515-1522.

Tabatabai, G. Zellbasierte Gentherapie maligner Gliome. 2012, University of Zurich, Faculty of Medicine.

Tabatabai, G; Hegi, M; Stupp, R; Weller, M (2012). Clinical implications of molecular neuropathology and biomarkers for malignant glioma. Current Neurology and Neuroscience Reports, 12(3):302-307.

Wolpert, F; Roth, P; Lamszus, K; Tabatabai, G; Weller, M; Eisele, G (2012). HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. Journal of Neuroimmunology, 250(1-2):27-34.

Hasenbach, K; Wiehr, S; Herrmann, C; Mannheim, J; Cay, F; von Kürthy, G; Bolmont, T; Grathwohl, S A; Weller, M; Lengerke, C; Pichler, B J; Tabatabai, G (2012). Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography. Neuro-oncology, 14(4):471-481.

Wick, W; Platten, M; Meisner, C; Felsberg, J; Tabatabai, G; Simon, M; Nikkhah, G; Papsdorf, K; Steinbach, J P; Sabel, M; Combs, S E; Vesper, J; Braun, C; Meixensberger, J; Ketter, R; Mayer-Steinacker, R; Reifenberger, G; Weller, M (2012). Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, 13(7):707-715.

Eisele, G; Roth, P; Hasenbach, K; Aulwurm, S; Wolpert, F; Tabatabai, G; Wick, W; Weller, M (2011). APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro-Oncology, 13(2):155-164.

Schraivogel, D; Weinmann, L; Beier, D; Tabatabai, G; Eichner, A; Zhu, J Y; Anton, M; Sixt, M; Weller, M; Beier, C P; Meister, G (2011). CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells. The EMBO Journal, 30(20):4309-4322.

Tabatabai, G; Weller, M (2011). Glioblastoma stem cells. Cell and Tissue Research, 343(3):459-465.

Tabatabai, G; Wick, W; Weller, M (2011). Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach? Discovery medicine, 11(61):529-536.

Tabatabai, G; Tonn, J C; Stupp, R; Weller, M (2011). The role of integrins in glioma biology and anti-glioma therapies. Current Pharmaceutical Design, 17(23):2402-2410.

Roth, P; Junker, M; Tritschler, I; Mittelbronn, M; Dombrowski, Y; Breit, S N; Tabatabai, G; Wick, W; Weller, M; Wischhusen, J (2010). GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clinical Cancer Research, 16(5):3851-3859.

Tabatabai, G; Stupp, R (2010). Angiogenesehemmung in der Neuroonkologie: Eine vielversprechende Therapiestrategie gegen maligne Gliome. Der Nervenarzt, 81(8):936-939.

Tabatabai, G; Hasenbach, K; Herrmann, C; Maurer, G; Möhle, R; Marini, P; Grez, M; Wick, W; Weller, M (2010). Glioma tropism of lentivirally transduced hematopoietic progenitor cells. International Journal of Oncology, 36(6):1409-1417.

Tabatabai, G; Stupp, R; van den Bent, M J; Hegi, M E; Tonn, J C; Wick, W; Weller, M (2010). Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathologica, 120(5):585-592.

Weller, M; Wick, W; Hegi, M E; Stupp, R; Tabatabai, G (2010). Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? Future Oncology, 6(9):1407-1414.

Miller, J; Eisele, G; Tabatabai, G; Aulwurm, S; von Kürthy, G; Stitz, L; Roth, P; Weller, M (2010). Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. Journal of Neurosurgery, 113(2):280-285.

Tabatabai, G; Weller, M; Nabors, B; Picard, M; Reardon, D; Mikkelsen, T; Ruegg, C; Stupp, R (2010). Targeting integrins in malignant glioma. Targeted Oncology, 5(3):175-181.

Gramatzki, D; Pantazis, G; Schittenhelm, J; Tabatabai, G; Köhle, C; Wick, W; Schwarz, M; Weller, M; Tritschler, I (2009). Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene, 28(28):2593-2605.

Maurer, G D; Tritschler, I; Adams, B; Tabatabai, G; Wick, W; Stupp, R; Weller, M (2009). Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-Oncology, 11(6):747-756.

Schittenhelm, J; Beschorner, R; Simon, P; Tabatabai, G; Herrmann, C; Schlaszus, H; Capper, D; Weller, M; Meyermann, R; Mittelbronn, M (2009). Diagnostic value of WT1 in neuroepithelial tumours. Neuropathology and Applied Neurobiology, 35(1):69-81.

Tabatabai, G; Stupp, R (2009). Primetime for antiangiogenic therapy. Current Opinion in Neurology, 22(6):639-644.

Rieger, J; Lemke, D; Maurer, G; Weiler, M; Frank, B; Tabatabai, G; Weller, M; Wick, W (2008). Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. Journal of Neurochemistry, 106(6):2436-2448.

Tabatabai, G; Herrmann, C; von Kürthy, G; Mittelbronn, M; Grau, S; Frank, B; Möhle, R; Weller, M; Wick, W (2008). VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. Brain: A Journal of Neurology, 131(10):2579-2595.

Haegele, L; Ingold, B; Naumann, H; Tabatabai, G; Ledermann, B; Brandner, S (2003). Wnt signalling inhibits neural differentiation of embryonic stem cells by controlling bone morphogenetic protein expression. Molecular and Cellular Neuroscience, 24(3):696-708.

This list was generated on Thu Feb 22 02:55:38 2018 CET.